Benzothiadiazoles
eMolecules 352018-95-2 | 4-IODO-2,1,3-BENZOTHIADIAZOLE | AstaTech | MFCD02681904 | 262.070 | C6H3IN2S | 95.000 | Ic1cccc2nsnc12 | 5g | 277517082
4-IODO-2,1,3-BENZOTHIADIAZOLE | AstaTech | 352018-95-2 | MFCD02681904 | 262.070 | C6H3IN2S | 95.000 | Ic1cccc2nsnc12 | 5g | 277517082
Accela Chembio Inc 2 | 1 | 3-benzothiadiazole | 100g | 273-13-2 | MFCD00005809 | 97+% | Shelf Life: 1260 Days | Light Sensitive/+4
2 | 1 | 3-benzothiadiazole | 100g | 273-13-2 | MFCD00005809 | 97+% | Shelf Life: 1260 Days | Light Sensitive/+4
![Medchemexpress LLC S-[2-[6-[[4-[3-(dimethylamino)propoxy]phenyl]sulfonylamino]-3-pyridinyl]-2-oxoethyl] ethanethioate | 940943-37-3 | MFCD19690928 | 98.1% | 451.56 | C20H25N3O5S2 | 10 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000241454.png-250.jpg)
Medchemexpress LLC S-[2-[6-[[4-[3-(dimethylamino)propoxy]phenyl]sulfonylamino]-3-pyridinyl]-2-oxoethyl] ethanethioate | 940943-37-3 | MFCD19690928 | 98.1% | 451.56 | C20H25N3O5S2 | 10 MG
KD 5170 is a small-molecule pan inhibitor of histone deacetylases (HDACs) that demonstrates broad-spectrum antitumor activity in vitro and in vivo. It is offered for laboratory research use and includes recommended solubility and storage guidance for experimental applications.
- Pan inhibitor of histone deacetylases (HDACs).
- Demonstrates broad-spectrum antitumor activity in vitro and in vivo.
- High purity (≈98.1%).
- Molecular formula C20H25N3O5S2; molecular weight 451.56.
- Soluble in DMSO (100 mg/mL); in vivo formulations documented at 2.5 mg/mL in common vehicles.
- Store sealed at 4°C; in solvent store at -80°C for long-term stability.
Medchemexpress LLC FAUC 213 | 337972-47-1 | 99.9% | C18H19ClN4 | 10 MM 1 ML
FAUC 213 is an orally active and highly selective dopamine D4 receptor complete antagonist with a Ki of 2.2 nM for hD4.4. It has less activity on D2 and D3 receptors (Kis of 3.4 μM, 5.3 μM for hD2, hD3, respectively) and can cross the blood-brain barrier (BBB). FAUC 213 exhibits atypical antipsychotic characteristics.
- Orally active
- Highly selective dopamine D4 receptor complete antagonist
- Ki of 2.2 nM for hD4.4
- Less activity on D2 and D3 receptors (Kis of 3.4 μM, 5.3 μM for hD2, hD3, respectively)
- Can cross the blood-brain barrier (BBB)
- Exhibits atypical antipsychotic characteristics
eMolecules 352018-95-2 | 4-IODO-2,1,3-BENZOTHIADIAZOLE | AstaTech | MFCD02681904 | 262.070 | C6H3IN2S | 95.000 | Ic1cccc2nsnc12 | 1g | 248475689
4-IODO-2,1,3-BENZOTHIADIAZOLE | AstaTech | 352018-95-2 | MFCD02681904 | 262.070 | C6H3IN2S | 95.000 | Ic1cccc2nsnc12 | 1g | 248475689